Anti-tumor immune modulation and favorable survival outcomes in uterine corpus endometrial carcinoma: insights from PIK3CA/ARID1A co-mutation analysis

被引:0
作者
Han, Dongmei [1 ,2 ]
Wu, Caihong [1 ,2 ]
Jin, Hao [1 ,2 ,3 ]
机构
[1] Tianjin Canc Hosp, Airport Hosp, Ctr Precis Canc Med & Translat Res, Tianjin 300181, Peoples R China
[2] Tianjin Med Univ Canc Inst & Hosp, Ctr Precis Canc Med & Translat Res, 99 East 5th Rd, Tianjin 300060, Peoples R China
[3] Tianjin Canc Hosp, Clin Res Management Dept, Airport Hosp, Tianjin 300181, Peoples R China
基金
中国国家自然科学基金;
关键词
Uterine corpus endometrial carcinoma; PIK3CA; ARID1A; Co-mutation; Bioinformatics; Prognosis and immune modulation; UCEC;
D O I
10.1007/s12672-025-02422-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Uterine corpus endometrial carcinoma (UCEC) is the most prevalent cancer of the female reproductive system, posing significant risks to women's reproductive health and imposing considerable economic burdens on families and society due to high treatment costs. Methods The study population comprised 529 UCEC patients who were selected and retrieved from the cBioPortal public database for a comprehensive integrated analysis. This study aims to explore the prognostic significance of co-mutation in PIK3CA/ARID1A genes in UCEC, utilizing various bioinformatics approaches, including differential expression genes (DEGs) analysis, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, Gene Set Enrichment Analysis (GSEA), immune infiltration analysis, and the establishment of nomogram model. Results PIK3CA/ARID1A co-mutation group had a better prognosis than the other three groups. The co-mutation of PIK3CA/ARID1A was associated with a significantly improved overall survival (OS) in patients with UCEC and immunotherapy markers. This result was further corroborated in the MSK cohort, reinforcing the robustness of our observations. Our findings revealed that 222 genes were upregulated and 1,464 genes downregulated in the co-mutation group compared to the non-co-mutation (NCM) group, providing a molecular basis for understanding the biological roles of these gene mutations in UCEC. Additionally, pathway analysis identified significant enrichment in immune-related pathways, emphasizing the potential for co-mutation to influence tumor progression via immune modulation. Notably, patients with co-mutations exhibited improved overall survival (P < 0.05), suggesting their role as vital prognostic markers. The developed Cox proportional hazards model demonstrated high predictive accuracy (C-index = 0.835), supporting personalized management for UCEC patients. Conclusion In conclusion, this study underscores the importance of PIK3CA and ARID1A co-mutations in UCEC, advocating for their further exploration in clinical applications and therapeutic strategies.
引用
收藏
页数:15
相关论文
共 36 条
[1]   PIK3CA mutations and their impact on survival outcomes of patients with endometrial cancer: A systematic review and meta-analysis [J].
Bredin, Hanna K. ;
Krakstad, Camilla ;
Hoivik, Erling A. .
PLOS ONE, 2023, 18 (03)
[2]   A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations [J].
Canaud, Guillaume ;
Hammill, Adrienne M. ;
Adams, Denise ;
Vikkula, Miikka ;
Keppler-Noreuil, Kim M. .
ORPHANET JOURNAL OF RARE DISEASES, 2021, 16 (01)
[3]   MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma [J].
Chen, Junyu ;
Wu, Shan ;
Wang, Junwei ;
Han, Chunying ;
Zhao, Lijing ;
He, Kang ;
Jia, Yan ;
Cui, Manhua .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2023, 27 (12) :1708-1724
[4]  
Chen W., 2022, Oncol Rep, V47, P8
[5]   Therapeutic significance of ARID1A mutation in bladder cancer [J].
Conde, Marina ;
Frew, Ian J. .
NEOPLASIA, 2022, 31
[6]   Endometrial cancer [J].
Crosbie, Emma J. ;
Kitson, Sarah J. ;
McAlpine, Jessica N. ;
Mukhopadhyay, Asima ;
Powell, Melanie E. ;
Singh, Naveena .
LANCET, 2022, 399 (10333) :1412-1428
[7]   Integrated analysis and experiments uncover the function of disulfidptosis in predicting immunotherapy effectiveness and delineating immune landscapes in uterine corpus endometrial carcinoma [J].
Han, Lei ;
Li, Yilin ;
Yu, Yanjie ;
Liu, Guo ;
Gao, Xiangqian ;
Wang, Fei ;
Chen, Weiwei ;
Xu, Huishu ;
Zhang, Baolin ;
Xu, Yingjiang ;
Pan, Yitong ;
Huang, Yu ;
Yi, Ping .
FRONTIERS IN IMMUNOLOGY, 2024, 15
[8]   Comprehensive Mutation Profiling of Colorectal Cancer Patients With Lung or Liver Metastasis by Targeted Next-Generation Sequencing [J].
Hu, Chun-Ting ;
Wang, Jing-Long ;
Hou, Ting ;
Yan, Zhao-Wen ;
Zu, Li-Dong ;
Fu, Guo-Hui ;
Shen, Wei-Wei .
TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22
[9]   Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer [J].
Jiang, Zhansheng ;
Zhu, Mingyu ;
Zhang, Lu ;
Cui, Haiyan ;
Jiang, Richeng ;
Yang, Yanfang .
GYNECOLOGIC ONCOLOGY, 2024, 187 :1-11
[10]   Integrated in silico analysis of LRP2 mutations to immunotherapy efficacy in pan-cancer cohort [J].
Li, Chunbo ;
Ding, Yan ;
Zhang, Xuyin ;
Hua, Keqin .
DISCOVER ONCOLOGY, 2022, 13 (01)